Literature DB >> 8866656

Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma.

M V Pimm1, A C Perkins, J Strohalm, K Ulbrich, R Duncan.   

Abstract

An N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin conjugate is currently under clinical evaluation as a new antitumour agent. It has been shown previously that such conjugates exhibit selective tumour accumulation. In this study HPMA copolymer doxorubicin conjugates of low (LMW) or high (HMW) molecular weight were synthesised (which had a weight average molecular weight (Mw) of 25,000 and 94,000 respectively) and additionally contained a small amount (1 mol%) of the comonomer methacryloyltyrosinamide to permit labelling with [123I or 125I]iodide. Gamma camera imaging using the 123I-labelled probes was used to follow time-dependent biodistribution after intraperitoneal (i.p.) or intravenous (i.v.) administration to mice bearing subcutaneously either B16F10 melanoma or a mammary carcinoma. Imaging showed more rapid clearance of LMW conjugate from the peritoneal cavity than HMW conjugate. The images of mice given the LMW conjugate revealed rapid urinary excretion of radioactivity after both i.p. and i.v. injection with an early high concentration of tracer in the bladder, and subsequently a very high concentration in the kidneys, which came to dominate the views. Dissection analysis 2 days after administration of the LMW conjugate revealed a kidney level of radioactivity corresponding to 25-40% dose/g tissue in mice bearing the two tumour models. Following administration of the HMW conjugate kidney accumulation at 2 days was less due to retention of the higher molecular weight polymer molecules in the circulation, and spleen and liver displayed the highest concentrations of radioactivity. The tumour accumulation of LMW and HMW conjugates was; mammary carcinoma 3.18 and 5.29% dose/g respectively; B16F10 melanoma 3.23 and 8.82 %dose/g although these levels of tracer enabled visualisation in the images of the mammary carcinoma with HMW conjugate at later time points. The smaller size of the B16F10 tumour masses did not permit clear visualisation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866656     DOI: 10.3109/10611869608996828

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

Review 1.  Polymeric materials for theranostic applications.

Authors:  Zhe Wang; Gang Niu; Xiaoyuan Chen
Journal:  Pharm Res       Date:  2013-06-14       Impact factor: 4.200

2.  177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model.

Authors:  Sunny M Ogbomo; Wen Shi; Nilesh K Wagh; Zhengyuan Zhou; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2013-04-24       Impact factor: 2.408

3.  Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.

Authors:  Ling-Dong Quan; Fang Yuan; Xin-Ming Liu; Jian-Geng Huang; Yazen Alnouti; Dong Wang
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation.

Authors:  Bahar Zarabi; Anjan Nan; Jiachen Zhuo; Rao Gullapalli; Hamidreza Ghandehari
Journal:  Macromol Biosci       Date:  2008-08-11       Impact factor: 4.979

5.  Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI.

Authors:  Yanli Wang; Furong Ye; Eun-Kee Jeong; Yongen Sun; Dennis L Parker; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2007-03-27       Impact factor: 4.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.